A fund bought BLCO shares earlier, and the company expects a higher 2026 profit forecast after a strong preliminary quarter. But the FDA cited recurring factory contamination, and a dry-eye trial missed its main goal, leaving the company's outlook unchanged by this mixed report.
The earlier fund investment shows interest, but it does not change BLCO's business by itself. The strong early quarter and expected higher profit forecast point up. FDA contamination findings and a missed main trial goal point down, so the story does not clearly change BLCO's outlook.
Follow Bausch + Lomb Corp. (BLCO) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for BLCO